CD44 targeted delivery of hyaluronic-acid-coated polymeric nanoparticles against colorectal cancer

• Published in: Nanomedicine (London, England) Vol. 18; no. 23; pp. 1613 - 1634
• Main Authors: Phatak, Niraj, Bhattacharya, Sankha, Shah, Disha, Manthalkar, Laxmi, Sreelaya, Putrevu, Jain, Arinjay
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.10.2023
• Subjects: Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; CD44 receptor; Cell Line, Tumor; Colonic Neoplasms - drug therapy; colorectal cancer; Drug Carriers; HCT116; Hyaluronic Acid; Lactic Acid; Male; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; polymeric nanoparticles; Rats; sorafenib tosylate; targeted drug delivery; sorafenib tosylate; colorectal cancer; polymeric nanoparticles; HCT116; targeted drug delivery; CD44 receptor; hyaluronic acid
• ISSN: 1743-5889; 1748-6963
• DOI: 10.2217/nnm-2023-0145

To develop hyaluronic acid (HA)-coated poly-lactic-co-glycolic acid (PLGA)-polysarcosine (PSAR) coupled sorafenib tosylate (SF) polymeric nanoparticles for targeted colon cancer therapy. PLGA–PSAR shells were encapsulated with SF via nanoprecipitation. Interactions were examined with transmission electron microscopy, revealing formulation component interactions. The optimized HA-coated polymeric nanoparticles (238.8 nm, -6.1 mV, 68.361% entrapment) displayed enhanced controlled release of SF. These formulations showed superior cytotoxicity against HCT116 cell lines compared with free drug (p < 0.05). tests on male albino Wistar rats demonstrated improved pharmacokinetics, targeting and biocompatibility. HA-coated PLGA–PSAR-coupled SF polymeric nanoparticles hold potential for effective colorectal therapy. Colon cancer may be precisely targeted by HA-coated PLGA–PSA-coupled SF polymeric nanoparticles.